At study completion on day 34, 80% of the mice that received both DBTEs survived the challenge, whereas 20% in the EGFRvIII-DBTE group, 10% in HER2-DBTE group, and 0% in pVAX1 group survived the heterogeneous GBM challenge (Figure 8F). Here, ERBB2 is linked to glioblastoma.